BDTX vs ARVN vs KYMR vs PRAX

For growth investors, Arvinas, Inc.

(ARVN) is the stronger pick with -0. 3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Black Diamond Therapeutics, Inc. (BDTX) offers the better valuation at 7. 2x trailing P/E, making it the more compelling value choice. Analysts rate Black Diamond Therapeutics, Inc. (BDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +110. 5%, compared to -89. 0% for Black Diamond Therapeutics, Inc. (BDTX). Over 10 years, the gap is even starker: KYMR returned +159. 4% versus BDTX's -92. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arvinas, Inc.

(ARVN) is the lower-risk stock at 1. 15β versus Black Diamond Therapeutics, Inc. 's 2. 66β — meaning BDTX is approximately 132% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 13% for Black Diamond Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arvinas, Inc.

(ARVN) is pulling ahead at -0. 3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Black Diamond Therapeutics, Inc. grew EPS 130. 7% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Black Diamond Therapeutics, Inc.

(BDTX) is the more profitable company, earning 30. 7% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 30. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDTX leads at 16. 9% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +159. 4% 10Y return). Black Diamond Therapeutics, Inc. (BDTX) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +159. 4%, BDTX: -92. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDTX is a small-cap deep-value stock; ARVN is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.